JPMorgan Upgrades Integra LifeSciences (IART) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Integra LifeSciences (IART) Tops Q2 EPS by 3c; Updates FY15 Outlook
July 30, 2015 8:51 AM EDTIntegra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.79, $0.03 better than the analyst estimate of $0.76. Revenue for the quarter came in at $0 versus the consensus estimate of $239.91 million.
Integra LifeSciences sees FY2015 EPS of $3.00-$3.10, versus the consensus of $3.11. Integra LifeSciences sees FY2015 revenue of... More
